Melanoma Research Alliance announces $11.8 Million in 28 research grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Melanoma Research Alliance has announced funding for 28 research grants totaling $11.8 million.

The awards will fund researchers at 23 institutions from across the United States, Australia, and Belgium to accelerate research and advance the prevention, diagnosis and treatment of melanoma.

This year’s grant awards will support 13 Team Science Awards and 15 Young Investigator Awards. Together, these awards represent the single largest grant year ever by the Melanoma Research Alliance and brings the total invested by the organization to over $100 million.

These 28 research projects will accelerate research addressing critical issues in melanoma, including identifying novel drug targets, treatments and biomarkers, as well as studies aimed at preventing melanoma or improving methods of early detection.

Several research projects will provide critical advancements in the understanding of rare and difficult-to-treat melanoma subtypes. Six awards will examine new therapeutic interventions to determine how specific genetic alterations contribute to the development and progression to acral lentiginous melanoma.

MRA’s 2018 grants are made possible through the significant contributions of individuals, families, institutions and corporate allies. Donors and partners providing financial support for 75% or more of an award are listed below within the award naming.

YOU MAY BE INTERESTED IN

In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transformed the field. 
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login